Cases of immunotherapy induced sarcoid and sarcoid-like granulomatous reaction in metastatic melanoma

Age*, Sex	Stage	Immunotherapy (cycle prior to sarcoid diagnosis)	Melanoma Response	Sarcoid Organ Involvement	Symptoms related to Sarcoid	Sarcoid Treatment Required	Reference
67 F	IV	Ipilimumab (4+)	stable disease	lung, mediastinum, skin	dyspnea	unknown	[5]
62 F	IV	Ipilimumab (not reported)	stable disease	mediastinal LN, skin, bronchus	none	No	[6]
49 M	IV	Ipilimumab (4)	complete response	mediastinal/hilar LN	none	N0	[7]
48 F	IV	Ipilimumab (2)	progression	Widespread LN, lung, spleen	dyspnea, cough, fatigue	Yes - steroids	[8]
63 M	IV	Ipilimumab (4)	progression	lung	dyspnea, dry cough, hypoxia	Yes-steroids	[9]
57 M	IIIB	Ipilimumab (6)	Unknown	lung, hilar LN, skin	none	No	[10]
55 M	IIIB	Ipilimumab (2)	progression	lung, mediastinal/hilar LN, skin	dyspnea, hypoxia	Yes-steroids	[11]
37 M	IV	Ipilimumab (4)	stable disease	mediastinal/hilar LN, brain	fatigue, arthralgia, anorexia, weight loss, headache	Yes-steroids	[12]
44 M	IV	Ipilimumab (4)	partial response	spleen	none	No	[13]
57 M	IV	Nivolumab (not reported)	complete response	mediastinal/hilar LN, skin	none	No	[14]

*Age at initial diagnosis of melanoma